美女av爆操国产_五月天丁香七月深爱激情网_日韩欧美内地福利_国产麻豆精品_亚洲一区乱码精品中文_亚洲第一乱码字幕小综合_国产剧情精品91一区二区_嗯啊羞羞视频在线观看动漫_影音先锋AV成人电影_日韩在线视频导航

“A Randomized, Single-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD5044 in Healthy Subjects”, this study is ongoing in Australia. the study is currently in the single-dose incremental enrolment phase.

RBD4059 is a GalNAc-siRNA drug that inhibits FXI activity and prolongs APTT to achieve anticoagulant effects. As demonstrated in preclinical data, RBD4059 has a long-lasting and potent antithrombotic effect combined with a favorable safety profile. RBD4059 is the first FXI targeting siRNA drug that that has entered the clinical stage.